Ipamorelin: Mechanism, Research Dosing, and Side Effects

What is ipamorelin?

Ipamorelin is a lab-made pentapeptide, a chain of five amino acids, that belongs to the growth hormone releasing peptide (GHRP) family and acts as a growth hormone secretagogue.

A secretagogue is a compound that tells a gland to release something it already makes. Ipamorelin does not contain growth hormone. Instead it binds a receptor on the pituitary gland and nudges the gland to release a pulse of the body's own growth hormone (Raun et al., Eur J Endocrinol 1998, 139(5):552-561, PMID 9849822). That distinction matters for how people frame it. Ipamorelin is not synthetic growth hormone and it is not a steroid. It sits in the same broad family as older GHRPs like GHRP-6, but it was designed to be cleaner in its effects, which is the whole reason it drew attention.

Ipamorelin is also frequently discussed alongside CJC-1295, a longer-acting growth hormone releasing hormone (GHRH) analog, because the two act on the growth hormone axis through different receptors. That pairing is a separate topic with its own evidence and its own cautions. This page is about ipamorelin on its own. For the combination, see the CJC-1295 and ipamorelin dosage guide and the CJC-1295 and ipamorelin side effects guide.

One status point up front, covered in full lower down: ipamorelin is not an approved medicine. It is a research compound, and the human data on it are limited to a small number of early studies.

How does ipamorelin work?

Ipamorelin binds the growth hormone secretagogue receptor (the ghrelin receptor, GHS-R1a) and stimulates the pituitary to release a pulse of growth hormone, which in turn raises IGF-1.

There are two separate switches the body uses to control growth hormone. One is the GHRH receptor, activated by growth hormone releasing hormone. The other is the growth hormone secretagogue receptor, GHS-R1a, which is the receptor the stomach hormone ghrelin normally activates. Ipamorelin works on that second switch. In the paper that introduced it, ipamorelin was shown to stimulate growth hormone release through a GHRP-like receptor, the same pathway used by the older peptide GHRP-6 (Raun et al., Eur J Endocrinol 1998, 139(5):552-561, PMID 9849822). Once growth hormone is released into the blood, it travels to the liver and other tissues and drives production of insulin-like growth factor 1 (IGF-1), the downstream signal behind many of growth hormone's effects.

Two features of this mechanism are worth understanding. First, because ipamorelin acts upstream, on the gland rather than replacing the hormone, the body's own controls still operate. Growth hormone secretagogues tend to produce pulses of hormone rather than a flat, constant level, which is closer to the body's natural rhythm. Second, and this is ipamorelin's signature, the receptor it hits can in principle trigger other pituitary outputs too, and the finding that ipamorelin largely did not do that is exactly what set it apart. That selectivity story is the next section.

Why is ipamorelin called a "selective" growth hormone secretagogue?

Because in its founding study, ipamorelin raised growth hormone without significantly raising the stress hormone cortisol, its trigger ACTH, or prolactin, a selectivity that earlier peptides in its class did not have.

This is the heart of what makes ipamorelin different, so it is worth reporting precisely. Raun and colleagues tested ipamorelin against GHRP-6 and other secretagogues. For releasing growth hormone, ipamorelin was comparably potent to GHRP-6: in vitro its half-maximal concentration (EC50) was about 1.3 nmol/l versus about 2.2 nmol/l for GHRP-6, and in conscious swine the dose producing half the maximum growth hormone response (ED50) was about 2.3 nmol/kg for ipamorelin versus about 3.9 nmol/kg for GHRP-6 (Raun et al., Eur J Endocrinol 1998, 139(5):552-561, PMID 9849822). So on growth hormone, the two are close.

The difference is in what else they did. The authors reported that ipamorelin did not release ACTH or cortisol at levels significantly different from what growth hormone releasing hormone itself caused, and, importantly, that this lack of effect held even at doses more than 200 times the ED50 for growth hormone release (Raun et al., Eur J Endocrinol 1998, 139(5):552-561, PMID 9849822). They also reported that none of the secretagogues tested, ipamorelin included, affected FSH, LH, prolactin, or TSH plasma levels. That combination, a strong and clean growth hormone signal with a selectivity profile similar to GHRH, is why the paper's title calls ipamorelin "the first selective growth hormone secretagogue." It is the single most-cited fact about this peptide, and it comes straight from the primary source.

What does research report on ipamorelin benefits?

The published human research on ipamorelin measured hormone changes, mainly a pulse of growth hormone, and pharmacokinetics, not body-composition outcomes in healthy people, so the honest read is limited to what was actually recorded.

The clearest human data come from a pharmacokinetic and pharmacodynamic study in 40 healthy male volunteers who received ipamorelin by short intravenous infusion (Gobburu et al., Pharm Res 1999, 16(9):1412-1416, PMID 10496658). That study reported that ipamorelin produced a single episode of growth hormone release, with the peak arriving early, at about 0.67 hours, then declining. In other words, ipamorelin did in people what the animal work predicted: it triggered a brief, clean pulse of growth hormone. IGF-1 is worth understanding alongside this, because it is the more stable readout. The National Library of Medicine notes that IGF-1 manages many of growth hormone's effects, and that because growth hormone levels swing through the day while IGF-1 stays steadier, measuring IGF-1 is a reliable way to track growth hormone activity (MedlinePlus, "IGF-1 (Insulin-like Growth Factor 1) Test," U.S. National Library of Medicine, https://medlineplus.gov/lab-tests/igf-1-insulin-like-growth-factor-1-test/).

What the research does not establish is a promised result for a reader. Fat loss, muscle gain, better sleep, or an anti-aging effect on a timeline are the claims most often attached to ipamorelin online, and the controlled human trials that would prove them in healthy adults have not been done. Raun et al. measured hormone release and selectivity in animals and cells; Gobburu et al. measured pharmacokinetics and the growth hormone pulse in healthy men. Neither measured a body-composition outcome. Treat the growth hormone pulse as what it is, evidence that the axis responded, and treat everything downstream of it as unproven in this context. For how this whole class is studied against lean-mass and fat-loss questions, see the peptides for muscle growth hub and the peptides for fat loss hub.

What dosing does ipamorelin research report?

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Here is the honest situation with ipamorelin doses. The rigorous published numbers are pharmacology and pharmacokinetic figures from animals and from an intravenous infusion study in healthy men, not a validated subcutaneous dose for general use. The animal potency figures are reported as ED50 values, the dose producing half the maximum growth hormone response, in nanomoles per kilogram. An ED50 is a potency measurement, not a dosing instruction, and it does not convert into a "dose to take." The human study used timed intravenous infusions expressed in nanomoles per kilogram, again a research design rather than a general protocol. The table shows exactly what each source used, with the source for each row.

A few things the table makes plain. The animal ED50 figures are potency measurements in nmol/kg, not a human dose, and the founding study did not set one. The human study used intravenous infusions to characterize pharmacokinetics, which is a different thing from a repeated subcutaneous research protocol. There is no trial-validated general subcutaneous dose of ipamorelin, so any fixed microgram figure circulating online is going past what the published record supports.

A note on unit math, shown generically as a reference and not as an instruction to the reader. Two conversions come up. First, nanomoles only become micrograms once you use the peptide's molar mass, and because ipamorelin's rigorous figures are potency and infusion values rather than a recommended dose, there is no meaningful reader-facing conversion to make from them. Second, a microgram figure only becomes a syringe reading after the peptide is dissolved in a known volume of liquid. As a generic example, if 5 mg of any peptide is dissolved in 2 mL of liquid, that is 2500 mcg per mL, and a U-100 insulin syringe reads 100 units per mL, so 1 mcg corresponds to 0.04 units on that scale and 1 unit corresponds to 25 mcg. Change the liquid volume and every number changes with it. This is arithmetic for reading a label, not guidance on what to draw. For the mechanics of dissolving a lyophilized peptide, see the reconstitution guide.

What are the side effects of ipamorelin?

The most-cited feature of ipamorelin is what it did not do, staying clean on cortisol, prolactin, and appetite hormones, but human safety data are thin and it is not an approved medicine.

Ipamorelin's selectivity is a tolerability story as much as a mechanism story. In the founding research, it raised growth hormone without significantly raising ACTH, cortisol, or prolactin, and without affecting FSH, LH, or TSH (Raun et al., Eur J Endocrinol 1998, 139(5):552-561, PMID 9849822). That is relevant because a related peptide, GHRP-6, is known for a strong appetite-stimulating effect and for modestly raising cortisol and prolactin at higher doses, effects tied to the same receptor. Ipamorelin was designed to avoid that broader footprint, and in the studies it largely did.

Two limits are worth stating plainly. First, "did not raise these hormones in a study" is not the same as "safe for a person over time." Growth hormone secretagogues as a class can cause transient injection-site reactions, flushing, headache, or water retention, and raising growth hormone and IGF-1 is not risk-free, which is why medical supervision is the norm in any clinical setting. Second, long-term human safety data specific to ipamorelin are not established. The human record is small and short. None of this amounts to a safety guarantee. Because purity matters for any injectable research compound, a certificate of analysis is worth reviewing (see [/coa]).

What is the half-life of ipamorelin?

Ipamorelin clears from the blood fairly quickly, with a reported terminal half-life of about 2 hours in healthy men, and the growth hormone pulse it triggers is brief.

The human pharmacokinetic study reported a short terminal half-life of about 2 hours, along with a clearance of about 0.078 L/h/kg and a steady-state volume of distribution of about 0.22 L/kg, after intravenous infusion in 40 healthy male volunteers (Gobburu et al., Pharm Res 1999, 16(9):1412-1416, PMID 10496658). The pharmacodynamics matched: ipamorelin produced a single episode of growth hormone release that peaked early, at about 0.67 hours, then declined to a negligible level. So both the peptide itself and the hormone pulse it causes are short-lived events, not a sustained elevation.

This short window is a large part of what distinguishes ipamorelin from long-acting agents on the growth hormone axis. A short blood half-life does not mean the downstream effect is equally short, because the growth hormone pulse and the IGF-1 response it drives outlast the peptide. But it does mean ipamorelin is cleared fast, which is why in research discussion it is often paired with a longer-acting GHRH analog: one provides a brief, sharp pulse, the other a sustained background signal. That contrast is the comparison below.

How does ipamorelin compare to CJC-1295 and GHRP-6?

Ipamorelin, CJC-1295, and GHRP-6 all raise growth hormone, but they split into two receptor families and differ sharply in duration and in how clean their effects are.

CJC-1295 sits in a different family. It is a GHRH analog, so it works on the GHRH receptor, not the ghrelin receptor. It was also engineered to last far longer. In two randomized, placebo-controlled, double-blind, ascending-dose trials in healthy adults aged 21 to 61, a single subcutaneous dose of CJC-1295 raised mean growth hormone roughly 2 to 10 fold with the effect sustained about 6 days or more, and raised IGF-1 about 1.5 to 3 fold for about 9 to 11 days, with an estimated half-life of about 5.8 to 8.1 days (Teichman et al., J Clin Endocrinol Metab 2006, 91(3):799-805, PMID 16352683). That is a completely different time course from ipamorelin's roughly 2-hour half-life and single early pulse (Gobburu et al., Pharm Res 1999, 16(9):1412-1416, PMID 10496658). Because they hit different receptors, the two are often studied together, which is the whole premise of the blend guides linked below.

GHRP-6 is ipamorelin's closest relative: same receptor family, both acting through the GHS-R1a ghrelin receptor. On growth hormone potency they are close, as the founding study showed, but GHRP-6 carries the broader footprint ipamorelin was designed to avoid, including a pronounced appetite effect and modest cortisol and prolactin elevations at higher doses (the appetite and hormone breadth of GHRP-6 is well described in the literature on this class; human trial data remain limited). Ipamorelin's clean selectivity, no significant ACTH, cortisol, or prolactin rise even at more than 200 times its growth hormone ED50, is precisely the contrast that named it (Raun et al., Eur J Endocrinol 1998, 139(5):552-561, PMID 9849822).

Which to consider depends on the question, and none of this is a recommendation to use any of them. For the pairing people ask about most, see the CJC-1295 and ipamorelin dosage guide and the CJC-1295 and ipamorelin side effects guide. For a related GHRH analog with a modern regulatory record, see tesamorelin. For a plain-language primer on the whole category, see what peptides are.

Contraindications and cautions

Ipamorelin is a research compound, not an approved medicine, so the honest position is that there is no clinical use guidance for it, and general cautions around raising the growth hormone axis apply.

The status fact matters here. Ipamorelin is not an FDA-approved drug, and it does not appear on the FDA's list of bulk drug substances that may be used in pharmacy compounding under section 503A (FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act). It sits outside approved medicine, and its regulatory standing for compounding has been the subject of ongoing FDA review rather than settled. Because ipamorelin raises growth hormone and IGF-1, the general cautions that apply to boosting that axis apply here: any active or suspected cancer is a setting where raising a growth signal warrants medical caution, and pregnancy and breastfeeding are groups where investigational use of any such compound is not supported by data. Anyone considering research use should review purity documentation (see [/coa]) and treat the absence of long-term human safety trials as a real limit, not a green light.

Common mistakes and storage notes

The most common mistake with ipamorelin is treating an animal potency figure as a human dose; the second is mishandling a peptide that must stay cold and dry until it is used.

On the data side, the error to avoid is repeated above but bears one clear statement: ipamorelin's rigorous published numbers are ED50 potency values in animals and infusion values in a pharmacokinetic study, not a validated subcutaneous dose, so any fixed "milligrams per week" figure online is an extrapolation, not a finding (Raun et al., Eur J Endocrinol 1998, 139(5):552-561, PMID 9849822; Gobburu et al., Pharm Res 1999, 16(9):1412-1416, PMID 10496658). On the handling side, peptides like ipamorelin generally ship as a freeze-dried (lyophilized) powder that is stable when kept cold and dry, and once dissolved they are far less stable and are kept refrigerated and protected from light. The specifics of preparing and storing a reconstituted peptide are their own topic; see the reconstitution guide. None of this is use guidance, it is handling and label context for a research material.